Human papillomavirus type 18 DNA load and 2-year cumulative diagnoses of cervical intraepithelial neoplasia grades 2-3

Journal of the National Cancer Institute

Volumn 101, Issue 3, 2009, Pages 153-161

  Xi, Long Fu ^a,b   Koutsky, Laura A ^b   Castle, Philip E ^c   Wheeler, Cosette M ^d   Galloway, Denise A ^e   Mao, Constance ^a   Ho, Jesse ^a   Kiviat, Nancy B ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN TISSUE; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRUS LOAD;

ADULT; ANALYSIS OF VARIANCE; BIOPSY; CARCINOMA, SQUAMOUS CELL; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLPOSCOPY; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMAN PAPILLOMAVIRUS 18; HUMANS; LINEAR MODELS; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TUMOR VIRUS INFECTIONS; VIRAL LOAD;

EID: 59749099345     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn461     Document Type: Article

References (53)

1. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
2. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121(3):621-632.
3. Bulk S, Berkhof J, Rozendaal L, et al. The contribution of HPV18 to cervical cancer is underestimated using high-grade CIN as a measure of screening efficiency. Br J Cancer. 2007;96(8):1234-1236.
4. Woodman CB, Collins S, Rollason TP, et al. Human papillomavirus type 18 and rapidly progressing cervical intraepithelial neoplasia. Lancet. 2003;361(9351):40-43.
5. Kurman RJ, Schiffman MH, Lancaster WD, et al. Analysis of individual human papillomavirus types in cervical neoplasia: a possible role for type 18 in rapid progression. Am J Obstet Gynecol. 1988;159(2):293-296.
6. Bergeron C, Barrasso R, Beaudenon S, Flamant P, Croissant O, Orth G. Human papillomaviruses associated with cervical intraepithelial neoplasia. Great diversity and distinct distribution in low- and high-grade lesions. Am J Surg Pathol. 1992;16(7):641-649.
7. Kovacic MB, Castle PE, Herrero R, et al. Relationships of human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res. 2006;66(20):10112-10119.
8. Swan DC, Tucker RA, Tortolero-Luna G, et al. Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. J Clin Microbiol. 1999;37(4):1030-1034.
9. Ylitalo N, Sorensen P, Josefsson AM, et al. Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet. 2000;355(9222):2194-2198.
10. Josefsson AM, Magnusson PK, Ylitalo N, et al. Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet. 2000;355(9222):2189-2193.
11. van Duin M, Snijders PJ, Schrijnemakers HF, et al. Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. Int J Cancer. 2002;98(4):590-595.
12. Moberg M, Gustavsson I, Gyllensten U. Type-specific associations of human papillomavirus load with risk of developing cervical carcinoma in situ. Int J Cancer. 2004;112(5):854-859.
13. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Pretet JL. Dynamics of HPV16 DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Virol. 2006;35(3):270-277.
14. Fiander AN, Hart KW, Hibbitts SJ, et al. Variation in human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J Med Virol. 2007;79(9):1366-1369.
15. Cricca M, Morselli-Labate AM, Venturoli S, et al. Viral DNA load, physical status and E2/E6 ratio as markers to grade HPV16 positive women for high-grade cervical lesions. Gynecol Oncol. 2007;106(3):549-557.
16. Bavin PJ, Giles JA, Deery A, et al. Use of semi-quantitative PCR for human papillomavirus DNA type 16 to identify women with high grade cervical disease in a population presenting with a mildly dyskaryotic smear report. Br J Cancer. 1993;67(3):602-605.
17. Cuzick J, Terry G, Ho L, Hollingworth T, Anderson M. Type-specific human papillomavirus DNA in abnormal smears as a predictor of high-grade cervical intraepithelial neoplasia. Br J Cancer. 1994;69(1):167-171.
18. Dalstein V, Riethmuller D, Pretet JL, et al. Persistence and load of high-risk HPV are predictors for development of high-grade cervical lesions: a longitudinal French cohort study. Int J Cancer. 2003;106(3):396-403.
19. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict risk of invasive cervical carcinoma. Br J Cancer. 2005;92(5):891-894.
20. Ho CM, Chien TY, Huang SH, Lee BH, Chang SF. Integrated human papillomavirus types 52 and 58 are infrequently found in cervical cancer, and high viral loads predict risk of cervical cancer. Gynecol Oncol. 2006;102(1):54-60.
21. Carcopino X, Henry M, Benmoura D, et al. Determination of HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. J Med Virol. 2006;78(8):1131-1140.
22. Flores R, Papenfuss M, Klimecki WT, Giuliano AR. Cross-sectional analysis of oncogenic HPV viral load and cervical intraepithelial neoplasia. Int J Cancer. 2006;118(5):1187-1193.
23. Snijders PJ, Hogewoning CJ, Hesselink AT, et al. Determination of viral load thresholds in cervical scrapings to rule out CIN 3 in HPV 16, 18, 31 and 33-positive women with normal cytology. Int J Cancer. 2006;119(5):1102-1107.
24. Ho CM, Cheng WF, Chu TY, et al. Human papillomaviral load changes in low-grade squamous intraepithelial lesions of the uterine cervix. Br J Cancer. 2006;95(10):1384-1389.
25. Schlecht NF, Trevisan A, Duarte-Franco E, et al. Viral load as a predictor of the risk of cervical intraepithelial neoplasia. Int J Cancer. 2003;103(4):519-524.
26. Schiffman M, Adrianza ME. ASCUS-LSIL Triage Study. Design, methods and characteristics of trial participants. Acta Cytol. 2000;44(5):726-742.
27. The ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am J Obstet Gynecol. 2003;188(6):1383-1392.
28. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1):357-361.
29. Peyton CL, Gravitt PE, Hunt WC, et al. Determinants of genital human papillomavirus detection in a US population. J Infect Dis. 2001;183(11):1554-1564.
30. Xi LF, Kiviat NB, Hildesheim A, et al. Human papillomavirus type 16 and 18 variants: race-related distribution and persistence. J Natl Cancer Inst. 2006;98(15):1045-1052.
31. Blizzard L, Hosmer DW. The log multinomial regression model for nominal outcomes with more than two attributes. Biom J. 2007;49(6):889-902.
32. Slinker BK, Glantz SA. Multiple linear regression is a useful alternative to traditional analyses of variance. Am J Physiol. 1988;255(3 pt 2):R353-R367.
33. Cox DR. Regression models and life tables. J R Stat Soc (Ser B). 1972;34:187-220.
34. Gravitt PE, Burk RD, Lorincz A, et al. A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev. 2003;12(6):477-484.
35. Sherman ME, Wang SS, Wheeler CM, et al. Determinants of human papillomavirus load among women with histological cervical intraepithelial neoplasia 3: dominant impact of surrounding low-grade lesions. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1038-1044.
36. Bekkers RL, Bulten J, Wiersma-van Tilburg A, et al. Coexisting high-grade glandular and squamous cervical lesions and human papillomavirus infections. Br J Cancer. 2003;89(5):886-890.
37. Hadzisejdc I, Krasevic M, Haller H, Grahovac B. Distribution of human papillomavirus types in different histological subtypes of cervical adenocarcinoma. Coll Antropol. 2007;31(suppl 2):97-102.
38. Zielinski GD, Snijders PJ, Rozendaal L, et al. The presence of high-risk HPV combined with specific p53 and p16INK4a expression patterns points to high-risk HPV as the main causative agent for adenocarcinoma in situ and adenocarcinoma of the cervix. J Pathol. 2003;201(4):535-543.
39. Duggan MA, Benoit JL, McGregor SE, Inoue M, Nation JG, Stuart GC. Adenocarcinoma in situ of the endocervix: human papillomavirus determination by dot blot hybridization and polymerase chain reaction amplification. Int J Gynecol Pathol. 1994;13(2):143-149.
40. Thierry F, Heard JM, Dartmann K, Yaniv M. Characterization of a transcriptional promoter of human papillomavirus 18 and modulation of its expression by simian virus 40 and adenovirus early antigens. J Virol. 1987;61(1):134-142.
41. Demeret C, Yaniv M, Thierry F. The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. J Virol. 1994;68(11):7075-7082.
42. Dong G, Broker TR, Chow LT. Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements. J Virol. 1994;68(2):1115- 1127.
43. Tan SH, Leong LE, Walker PA, Bernard HU. The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J Virol. 1994;68(10):6411-6420.
44. Thierry F, Howley PM. Functional analysis of E2-mediated repression of the HPV18 P105 promoter. New Biol. 1991;3(1):90-100.
45. Romanczuk H, Thierry F, Howley PM. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol. 1990;64(6):2849-2859.
46. Desaintes C, Demeret C. Control of papillomavirus DNA replication and transcription. Semin Cancer Biol. 1996;7(6):339-347.
47. Yasugi T, Benson JD, Sakai H, Vidal M, Howley PM. Mapping and characterization of the interaction domains of human papillomavirus type 16 E1 and E2 proteins. J Virol. 1997;71(2):891-899.
48. Vinokurova S, Wentzensen N, Kraus I, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68(1):307-313.
49. Cullen AP, Reid R, Campion M, Lorincz AT. Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. J Virol. 1991;65(2):606-612.
50. Hopman AH, Kamps MA, Smedts F, Speel EJ, Herrington CS, Ramaekers FC. HPV in situ hybridization: impact of different protocols on the detection of integrated HPV. Int J Cancer. 2005;115(3):419-428.
51. Hudelist G, Manavi M, Pischinger KI, et al. Physical state and expression of HPV DNA in benign and dysplastic cervical tissue: different levels of viral integration are correlated with lesion grade. Gynecol Oncol. 2004;92(3):873-880.
52. Manavi M, Hudelist G, Fink-Retter A, Gschwantler-Kaulich D, Pischinger K, Czerwenka K. Human papillomavirus DNA integration and messenger RNA transcription in cervical low- and high-risk squamous intraepithelial lesions in Austrian women. Int J Gynecol Cancer. 2008;18(2):285-294.
53. Xi LF, Kiviat NB, Galloway DA, Zhou XH, Ho J, Koutsky LA. Effect of cervical cytologic status on the association between human papillomavirus type 16 DNA load and the risk of cervical intraepithelial neoplasia grade 3. J Infect Dis. 2008;198(3):324-331.